Lancet系列研究:母亲接种RSV疫苗使婴儿住院风险降低约74%,欧洲可及性差异显著
Maternal vaccines protect babies from serious infections, but unequal access limits benefits across Europe
The Lancet Regional Health - Europe新系列研究指出,母亲接种呼吸道合胞病毒(RSV)疫苗与6月龄内婴儿下呼吸道感染住院风险降低约74%相关。对16394例妊娠的荟萃分析未观察到疫苗与早产之间的显著统计学关联。研究同时发现欧盟地区存在接种不平等,英国数据显示最贫困区域女性的接种几率比最富裕区域低72%。
系统综述显示母亲接种RSV疫苗使6月龄内婴儿相关住院风险降低约74%,欧洲地区存在显著的接种可及性差距。
Europe must act now to strengthen maternal vaccination during pregnancy and ensure all women and babies can benefit from a new generation of vaccines to protect against serious infections. That is according to a new Lancet Regional Health - Europe series led by Professor Asma Khalil at City St George's, University of London, which is being launched and presented at the 2026 Global Society for Maternal-Fetal Medicine Congress in Utrecht.
The series found maternal RSV vaccination was associated with an approximately 74% lower risk of hospitalization for RSV-related lower respiratory tract infection in babies younger than 6 months. However, evidence also suggests substantial inequalities in access, with one U.K. study finding women living in the most deprived areas had 72% lower odds of receiving vaccination than women living in the least deprived areas.
While scientific advances in maternal immunization are moving rapidly, health systems have not kept pace. Fragmented delivery models, unequal access, gaps in surveillance and uncertainty over responsibility for vaccine delivery continue to limit uptake and leave many women and babies without protection. These issues need to be tackled head-on in a coordinated manner.
Khalil, professor of obstetrics and maternal fetal medicine in the School of Health & Medical Sciences at City St George's, University of London, and chair of the series, said, "Maternal vaccination is one of the most powerful public health interventions, giving protection to both pregnant women and their babies from serious infectious diseases.
"We now have new vaccines becoming available and other vaccine candidates progressing through clinical development, but introducing a vaccine is only the first step. Women need timely access, trusted information and convenient services if these programs are to achieve their full benefit.
"Across Europe we continue to see substantial variation in uptake and persistent inequalities in access. Our series shows that countries should begin preparing now for the next generation of maternal vaccines rather than waiting until new programs are introduced."
Maternal RSV vaccination significantly reduces infant hospitalizations
Respiratory syncytial virus (RSV) is a common cause of a type of chest infection called bronchiolitis. It can cause breathing problems and may require hospital treatment. A systematic review and meta-analysis included in the series found maternal RSV vaccination was associated with an approximately 74% lower risk of hospitalization for RSV-related lower respiratory tract infection in babies younger than 6 months.
The pooled analysis of 16,394 pregnancies did not identify a statistically significant association between maternal RSV vaccination and preterm birth. Continued safety monitoring remains important as vaccination programs expand.
The findings provide reassurance about the real-world effectiveness of maternal RSV vaccination, while reinforcing the importance of delivering vaccination within the recommended gestational window, with sufficient time before birth for protective antibodies to develop and transfer to the baby.
However, evidence presented in the series suggests not all women are benefiting equally. One U.K. study included in the review found substantially lower maternal RSV vaccination uptake among women living in the most deprived areas (72% lower odds) than among those living in the least deprived areas.
New vaccines are coming but health systems must be ready
The series also highlights a growing pipeline of maternal vaccines that could help protect pregnant women from serious infections as well as newborn babies during the first weeks and months of life.
A different paper in press for the series, led by Professor Paul Heath from City St George's, examines the next generation of maternal vaccines in development. Among the most advanced candidates are vaccines against group B streptococcus (GBS), a leading cause of neonatal sepsis and meningitis worldwide.
The authors argue that countries should begin preparing now for future maternal immunization programs, including strengthening surveillance systems, developing delivery pathways and supporting health care professionals to discuss vaccination confidently with pregnant women, all before new vaccines receive regulatory approval.
Heath, professor of pediatric infectious diseases at City St George's, University of London, said, "We are entering a new era for maternal immunization. For decades we have understood the value of protecting mothers and babies through vaccination during pregnancy, but we are now seeing a pipeline of new vaccines that could prevent serious infections in the earliest months of life.
"The science is advancing quickly. The challenge now is ensuring health systems are ready to deliver these vaccines effectively, monitor their impact and make sure all families can benefit, regardless of where they live or what their circumstances are."
Call for coordinated action across Europe
In another paper in press for the series, researchers mapped maternal vaccination policies across all 53 countries in the World Health Organization (WHO) European Region and reviewed 163 studies and policy sources.
Common factors associated with higher uptake include vaccines being free at the point of care, offered as part of routine prenatal services, delivered by health care professionals with clear responsibility for recommending and administering vaccines, and supported by robust monitoring systems.
However, barriers including additional appointments, language difficulties, fragmented services and inconsistent recommendations continue to limit access for some women and families.
Experts highlight evidence of persistent inequalities in maternal vaccine uptake and say that coverage should be routinely monitored by factors including deprivation, ethnicity and migration status so that underserved communities are not left behind as new programs are introduced.
As new maternal vaccines are introduced, the series shines a light on the importance of robust surveillance systems. A review of maternal pertussis vaccination programs across seven European countries, accepted for publication, found substantial differences in how disease burden, vaccine uptake and program impact are monitored.
Researchers argue that stronger and more consistent surveillance systems will be essential as maternal immunization programs expand, helping policymakers understand vaccine effectiveness, safety and emerging inequalities.
"The Future of Maternal Vaccination" series therefore calls for:
- Maternal vaccination to become a routine component of prenatal care across Europe
- Stronger monitoring of vaccine uptake, safety and inequalities
- Better integration of maternity and immunization records
- Improved support for underserved communities
- Coordinated preparation for future maternal vaccine programs
- Establishment of a European coordination group for maternal vaccine rollout
- Development of a European Maternal Immunization Preparedness Plan
Strengthening vaccine safety assessment
Another focus of the series is vaccine safety assessment during pregnancy. It explores the WHO's new causality assessment approach, which is designed to help assess whether a health event in pregnancy occurring after vaccination may be related to vaccination or has another explanation.
Consistent assessment is essential for identifying potential safety signals and providing clear, trustworthy information to families.
Miscarriage, preterm birth and hypertensive disorders can occur during pregnancy regardless of vaccination status, and an event occurring after vaccination does not by itself establish that the vaccine caused it.
The authors note that structured safety assessment should complement wider surveillance systems, clinical studies and pregnancy registries as maternal vaccination programs expand.
Closing the evidence gap in pregnancy research
The series also highlights continuing challenges in generating evidence during pregnancy.
A review of vaccine research found that almost 95% of late-stage vaccine trials conducted between 2018 and 2023 explicitly excluded pregnant participants, limiting the availability of evidence directly relevant to pregnancy.
The series supports greater inclusion of pregnant women in research, alongside robust systems for evaluating vaccine safety during pregnancy and monitoring outcomes for mothers and babies.
Khalil added, "The evidence is clear that maternal vaccination can save lives and reduce serious illness in mothers and babies. Our challenge now is ensuring that these benefits reach all families, regardless of where they live or their circumstances. Achieving that will require coordinated action across health services, public health agencies and policymakers."
More information
Evelyn Balsells et al, Real-world evidence on maternal RSV vaccination uptake, effectiveness, and safety: a systematic review and meta-analysis, The Lancet Regional Health - Europe (2026). DOI: 10.1016/j.lanepe.2026.101847
How can Europe increase uptake of maternal vaccines?, The Lancet Regional Health - Europe (2026). DOI: 10.1016/j.lanepe.2026.101891
Key medical concepts
Who's behind this story?
Sadie Harley
BSc Life Sciences & Ecology. Microbiology lab background with pharmaceutical news experience in oil, gas, and renewable industries. Full profile →
Robert Egan
Bachelor's in mathematical biology, Master's in creative writing. Well-traveled with unique perspectives on science and language. Full profile →
Citation: Maternal vaccines protect babies from serious infections, but unequal access limits benefits across Europe (2026, October 8) retrieved 8 October 2026 from https://medicalxpress.com/news/2026-10-maternal-vaccines-babies-infections-unequal.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
来源:Medical Xpress · medicalxpress.com